Performance status as the central guide in managing primary gastrointestinal lymphoma

Figure 1 An Eastern Cooperative Oncology Group performance status -centered framework for individualized management of primary gastrointestinal lymphoma. A proposed clinical decision framework for primary gastrointestinal lymphoma that places Eastern Cooperative Oncology Group (ECOG) Performance status (PS) at the center of individualized management. Treatment intensity is stratified according to ECOG PS, with integration of molecular subtype, Helicobacter pylori status, anatomical site, and comorbidity burden. Continuous reassessment throughout the treatment course allows for dynamic adaptation of therapeutic strategies. H. pylori: Helicobacter pylori; PGIL: Primary gastrointestinal lymphoma; ECOG: Eastern Cooperative Oncology Group; PS: Performance status; GCB: Germinal center B-cell; non-GCB: Non-germinal center B-cell; R-CHOP: The name of a combination of cancer drugs; R: Rituximab; C: Cyclophosphamide; H: Doxorubicin; O: Vincristine; P: Prednisolone.